Saroja Pharma Industries India
- Market cap
- ₹ 16 Cr.
- P/E
- 9.3x
- P/B
- 0.95x
- 52-week range
- 28 – 43.65
- ROE
- 10%
- ROCE
- 13.4%
- Dividend yield
- 0%
- Debt / equity
- 0.83
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- NSE SME
About
Saroja Pharma Industries India Limited is an India-based company. The Company operates as a trader, exporter and supplier of specialty chemicals. It offers pharma active pharmaceutical ingredient (API) products which include Closantel Sodium Dihydrate, Furosemide, Oxfendazole, Rafoxanide, Trichlorocarbanilide (TCC), Clorsulon, Diethyl Carbamazine, Niclosamide, Pyrantel Pamoate, and Povidone lodine. It also offers pharma intermediates which include Intermediates for Amoxapine & Loxapine, Methyl-3-Amino-2-Thiophene Carboxy, Intermediates for Tiotropium Bromide, Intermediates for Suxamethonium, Intermediates for Brinzolamide, Intermediates for Lornoxicam, Intermediates for Linezolid, Intermediates for Glimepiride, Intermediates for Gefitinib, and Intermediates for Ezetimibe. It also offers Aluminium Chloride Anhydrous Powder, Triethylamine Hydrochloride, Potassium Carbonate Granules, Sodium Hydro Sulphide, Tetra Butyl Ammonium Bromide, and Chlorosulphonic Acid.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Saroja Pharma Industries India against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)9.3 against a typical 25.8: cheaper than most peers (1st = cheapest).18th of 129
- Sales growth+62.6% against a typical +25.9% from a year earlier.16th of 112
- Profit growth+173.7% against a typical +42.4% from a year earlier.19th of 102
- Size₹ 16.4 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).119th of 126
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 28 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
| 13 Nov 2024 | Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| 29 May 2024 | Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| 9 Nov 2023 | Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 27 | 24 | 21 | 19 | 19 | 35 | 39 | 31 |
| Expenses | 25 | 22 | 20 | 18 | 18 | 33 | 37 | 29 |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 |
| OPM % | 5.1% | 6.1% | 5.5% | 6.2% | 6.4% | 5% | 3.5% | 7.7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Tax % | 27.6% | 27% | 27.5% | 27.5% | 27.7% | 29.3% | 26.9% | 28.3% |
| Net Profit | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| EPS in Rs | 24.36 | 1.84 | 1.24 | 0.95 | 0.85 | 1.74 | 1.42 | 2.59 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 12%
- TTM
- 31%
- 10 Years
- —
- 5 Years
- 18%
- 3 Years
- 16%
- TTM
- 62%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −15%
- TTM
- —
- 10 Years
- —
- 5 Years
- 12%
- 3 Years
- 9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Saroja Pharma Industries India | ₹ 38.80 | ₹ 16 Cr. | 9.3x | 1x | 10% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Biju Gopinathan Nair
- Executive Chairman of the Board, Managing Director
- Yogita Maheshwari
- Chief Financial Officer
- Nikita Kumar
- Compliance Officer, Company Secretary
- Manish Dasharath Kamble
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.